Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results
Abstract
Epidemiological studies consistently show an elevated intake of fish and long-chain omega-3 polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduces the risk of developing neurodegenerative diseases, particularly dementia and Alzheimer's disease. These observations are supported by preclinical research, where a range of potential mechanisms have been identified, such as increasing neurogenesis, or regulating inflammation and neuroinflammation via the production of bioactive lipid mediators. However, the results of clinical trials have been inconsistent and mixed, and this may be due to the considerable heterogeneity in trial designs, but also a lack of appreciation of methodological complications unique to omega-3 PUFA research. In this review, we explore omega-3 PUFA specific methodological considerations based around participant selection and trial design. Participant-related aspects include baseline cognitive status, age, sex and genotype, whereas methodological aspects include placebo selection, DHA vs. EPA, chemical form and quality of the omega-3 PUFA preparation, and wider nutrient interactions. We also suggest how consideration of these factors should be included in the design and reporting of clinical trials, with the aim of increasing the validity and reproducibility of research in the field.
Related
- Dietary omega-3 polyunsaturated fatty acids interact with select gut microbes to produce bioactive metabolites found in infant gut metabolomes
- Omega-3 polyunsaturated fatty acid supplementation for the management of exercise-induced bronchoconstriction: a systematic review and meta-analysis
- Mesenchymal stromal cells in age-related neurodegenerative disorders: mechanisms, translational barriers, and precision strategies
- Can Music-Induced Brain Plasticity Delay Neurodegenerative Disorders in Musicians? Review and Cases
- The Functional Connectivity of Hallucinations in Psychiatric Disorders and Neurodegenerative Disorders: A Systematic Review
BibTeX
@article{dyall2026omega3,
title = {{Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results}},
author = {Simon Dyall and Mélanie Plourde},
journal = {Progress in Lipid Research},
year = {2026},
month = oct,
doi = {10.1016/j.plipres.2025.101356},
url = {https://hal.science/hal-05790393v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results
AU - Simon Dyall
AU - Mélanie Plourde
PY - 2026
DA - 2026/10/09
JO - Progress in Lipid Research
DO - 10.1016/j.plipres.2025.101356
UR - https://hal.science/hal-05790393v1
AB - Epidemiological studies consistently show an elevated intake of fish and long-chain omega-3 polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduces the risk of developing neurodegenerative diseases, particularly dementia and Alzheimer's disease. These observations are supported by preclinical research, where a range of potential mechanisms have been identified, such as increasing neurogenesis, or regulating inflammation and neuroinflammation via the production of bioactive lipid mediators. However, the results of clinical trials have been inconsistent and mixed, and this may be due to the considerable heterogeneity in trial designs, but also a lack of appreciation of methodological complications unique to omega-3 PUFA research. In this review, we explore omega-3 PUFA specific methodological considerations based around participant selection and trial design. Participant-related aspects include baseline cognitive status, age, sex and genotype, whereas methodological aspects include placebo selection, DHA vs. EPA, chemical form and quality of the omega-3 PUFA preparation, and wider nutrient interactions. We also suggest how consideration of these factors should be included in the design and reporting of clinical trials, with the aim of increasing the validity and reproducibility of research in the field.
SN - 0163-7827
SN - 1873-2194
ER -